Evidence map›Paper›PMID 38722855›Full record

ArticlePloS one2024

Creation and characterization of novel rat model for recessive dystrophic epidermolysis bullosa: Frameshift mutation of the Col7a1 gene leads to severe blistered phenotype.

William Stone, Chloe Strege, William Miller, Aron M Geurts, Michael Grzybowski, Megan Riddle, Christopher Lees, Cindy Eide, Douglas R Keene, Sara F Tufa and 3 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

William StoneDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.
Chloe StregeDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0001-5707-9416
William MillerDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.
Aron M GeurtsDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.ORCID 0000-0002-4347-2505
Michael GrzybowskiDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Megan RiddleDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0002-9557-217X
Christopher LeesDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.
Cindy EideDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0001-7314-2550
Douglas R KeeneResearch Department, Shriners Hospital for Children, Portland, Oregon, United States of America.
Sara F TufaResearch Department, Shriners Hospital for Children, Portland, Oregon, United States of America.
Davis SeeligComparative Pathology Shared Resource, College of Veterinary Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America.
John McGrathSt. John's Institute of Dermatology, King's College London (Guy's Campus), London, United Kingdom.ORCID 0000-0002-3708-9964
Jakub TolarDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0002-0957-4380

Funding

Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis BullosaR01AR063070 · NIAMS · UNIVERSITY OF MINNESOTA · PI Mark J Osborn, Jakub Tolar · 2013 to 2026
$4.5M
NIAMS NIH HHS R01 AR063070
6 · The paper itself

Abstract

Recessive dystrophic epidermolysis bullosa is a rare genodermatosis caused by a mutation of the Col7a1 gene. The Col7a1 gene codes for collagen type VII protein, a major component of anchoring fibrils. Mutations of the Col7a1 gene can cause aberrant collagen type VII formation, causing an associated lack or absence of anchoring fibrils. This presents clinically as chronic blistering, scarring, and fibrosis, often leading to the development of cutaneous squamous cell carcinoma. Patients also experience persistent pain and pruritus. Pain management and supportive bandaging remain the primary treatment options. The pathology of recessive dystrophic epidermolysis bullosa was first described in the 1980s, and there has since been a multitude of encouraging treatment options developed. However, in vivo research has been hindered by inadequate models of the disease. The various mouse models in existence possess longevity and surface area constraints, or do not adequately model a normal human disease state. In this paper, we describe a novel rat model of recessive dystrophic epidermolysis bullosa that offers an alternative to previous murine models. An 8-base pair deletion was induced in the Col7a1 gene of Lewis rats, which was subsequently found to cause a premature stop codon downstream. Homozygous mutants presented with a fragile and chronically blistered phenotype postnatally. Further histological analysis revealed subepidermal clefting and the absence of anchoring fibrils. The generation of this novel model offers researchers an easily maintained organism that possesses a larger surface area for experimental topical and transfused therapies to be tested, which may provide great utility in the future study of this debilitating disease.

Indexed as

Collagen Type VIIDisease Models, AnimalEpidermolysis Bullosa DystrophicaFrameshift MutationPhenotypeAnimalsBlisterGenes, RecessiveMaleRatsRats, Inbred LewSkinCollagen Type VII

Identifiers

PMID38722855
PMCPMC11081381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.